Compare · NVO vs RNXT
NVO vs RNXT
Side-by-side comparison of Novo Nordisk A/S (NVO) and RenovoRx Inc. (RNXT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RNXT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.28B, about 5033.8x RNXT ($39.0M).
- Over the past year, NVO is down 45.8% and RNXT is down 35.8% - RNXT leads by 9.9 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 6 for RNXT).
- NVO has more recent analyst coverage (25 ratings vs 2 for RNXT).
- Company
- Novo Nordisk A/S
- RenovoRx Inc.
- Price
- $43.97+2.76%
- $0.86+0.82%
- Market cap
- $196.28B
- $39.0M
- 1M return
- -6.43%
- +1.27%
- 1Y return
- -45.76%
- -35.84%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest RNXT
- RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
- RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
- RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
- RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
- Chief Financial Officer Voll Mark bought $19,690 worth of shares (25,000 units at $0.79), increasing direct ownership by 21% to 142,380 units (SEC Form 4)
- RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
- Amendment: SEC Form 10-K/A filed by RenovoRx Inc.
- SEC Form 10-Q filed by RenovoRx Inc.
- RenovoRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter